Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

Published:2016-12 Issue:10063 Volume:388 Page:2997-3005
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Robertson John F R,Bondarenko Igor M,Trishkina Ekaterina,Dvorkin Mikhail,Panasci Lawrence,Manikhas Alexey,Shparyk Yaroslav,Cardona-Huerta Servando,Cheung Kwok-Leung,Philco-Salas Manuel Jesus,Ruiz-Borrego Manuel,Shao Zhimin,Noguchi Shinzaburo,Rowbottom Jacqui,Stuart Mary,Grinsted Lynda M,Fazal Mehdi,Ellis Matthew J

Publisher

Elsevier BV

Subject

General Medicine

Reference22 articles.

1. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline;Rugo;J Clin Oncol,2016

2. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Breast,2014

3. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group;Nabholtz;J Clin Oncol,2000

4. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma;Bonneterre;Cancer,2001

5. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group;Mouridsen;J Clin Oncol,2001

Cited by 457 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review;Critical Reviews in Oncology/Hematology;2024-10

2. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study;Journal of Clinical Oncology;2024-09-06

3. Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?;ESMO Open;2024-09

4. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer;Nature Reviews Clinical Oncology;2024-08-23

5. UBE2M forms a positive feedback loop with estrogen receptor to drive breast cancer progression and drug resistance;Cell Death & Disease;2024-08-13